Editorial and Review Standards

Who publishes this

Peptide Navigator is published by Meridian Spectre LLC, a United States limited liability company. Content is researched and written in-house under the Peptide Navigator name. We attribute our work to the organization rather than inventing individual authors, a medical reviewer, or a review board we do not have.

How we research

We build every guide from primary sources first: peer-reviewed studies indexed on PubMed or PMC, the original journal articles, and official regulatory documents such as FDA advisory committee materials and anti-doping rules. We open and read the actual research rather than repeating what other sites claim about it. When we describe evidence, we separate animal studies from human studies, and preliminary or single-source findings from well-replicated ones, because with peptides that distinction is usually the whole story.

How we choose sources, and what we reject

A source earns a place in a guide only if it clears a few tests:

• It has to be real and reachable. Every study we cite is opened and confirmed before it goes in. We link to the actual record on PubMed, PMC, or the journal, not to a summary of it.
• It has to support the claim. A study sits next to the specific thing it demonstrates, at the strength it demonstrates it. We do not stretch an in-vitro or animal result into a human one.
• Weak evidence is labeled, not dressed up. Small, uncontrolled, old, or single-group studies are described as exactly that.

What we reject: marketing pages, vendor claims, unsourced posts, and studies that do not say what a headline claims. When a claim has no adequate study behind it, we do not find a citation to prop it up. We change the claim to say the evidence is absent, because on this topic that is usually the correct answer.

How we check content

Before and after publishing, each guide is checked against the primary literature and the current regulatory status. This is an editorial check for accuracy and sourcing, not external peer review, and we do not describe it as more than that. If a qualified professional in pharmacy, medicine, nutrition, or fitness reviews a specific guide, that reviewer and their credential are named on the article itself. Where no such review has happened, we make no claim that it has.

Our editorial independence

Peptide Navigator earns revenue from educational ebooks, affiliate links, and advertising. Our conclusions are not for sale. We do not weaken an honest assessment to move a product, we do not accept payment to promote a specific peptide or vendor, and commercial relationships never determine whether we call the evidence strong or weak. If a popular, monetizable peptide has thin evidence, we say so plainly.

Corrections policy

When we get something wrong, we fix it and we say so. If you believe something is inaccurate or out of date, tell us through the contact page. We review every report, correct the content if warranted, update the article's last updated date, and record any substantive factual correction in the log below. Routine copyedits are not logged. Corrections that change a fact, a number, or a conclusion are.

Corrections log

Substantive factual corrections to published guides are listed here, newest first.

• September 12, 2026, FDA hearing article. An early published version described the number of newly appointed advisory committee members with peptide-clinic ties as "seven of the eight," based on a weak secondary source. We corrected the figure to "six of the eight" and attributed it inline to ABC News.

The rules we never break

These are hard lines on every piece of content we publish:

• No doses, no reconstitution math, no injection technique, and no cycling or tapering numbers.
• No sourcing, vendor names, or purchase links for unapproved peptides.
• No claim that anything is proven beyond what the actual evidence supports, and honest caveats when it does not.
• Every practical health decision is routed to a licensed clinician who knows the reader's history.